Demethylation of a LINE-1 antisense promoter in the cMet locus impairs Met signalling through induction of illegitimate transcription

Oncogene

Volumn 29, Issue 43, 2010, Pages 5775-5784

  Weber, B ^a   Kimhi, S ^b   Howard, G ^b   Eden, A ^b   Lyko, F ^a  

^a GERMAN CANCER RESEARCH CENTER   (Germany)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

azacytidine; cMet; decitabine; DNA methylation; LINE element

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; SCATTER FACTOR RECEPTOR;

ARTICLE; CARCINOMA CELL; CONTROLLED STUDY; DEMETHYLATION; GENE DISRUPTION; GENE EXPRESSION; GENE LOCUS; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LEUKEMIA CELL; LONG INTERSPERSED REPEAT; PRIORITY JOURNAL; PROMOTER REGION; RETROPOSON; UPREGULATION;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTISENSE ELEMENTS (GENETICS); AZACITIDINE; BLOTTING, WESTERN; CHROMATIN IMMUNOPRECIPITATION; DNA METHYLATION; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC LOCI; HCT116 CELLS; HL-60 CELLS; HUMANS; LONG INTERSPERSED NUCLEOTIDE ELEMENTS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-MET; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 78049349212     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.227     Document Type: Article

References (40)

1. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. (2003). Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4: 915-925.
2. Boyd KE, Farnham PJ. (1999). Coexamination of site-specific transcription factor binding and promoter activity in living cells. Mol Cell Biol 19: 8393-8399.
3. Breiling A, Turner BM, Bianchi ME, Orlando V. (2001). General transcription factors bind promoters repressed by Polycomb group proteins. Nature 412: 651-655.
4. 0-deoxycytidine. Mol Cancer Ther 4: 1515-1520.
5. Cruickshanks HA, Tufarelli C. (2009). Isolation of cancer-specific chimeric transcripts induced by hypomethylation of the LINE-1 antisense promoter. Genomics 94: 397-406.
6. Egger G, Liang G, Aparicio A, Jones PA. (2004). Epigenetics in human disease and prospects for epigenetic therapy. Nature 429: 457-463.
7. Ehrlich M. (2002). DNA methylation in cancer: too much, but also too little. Oncogene 21: 5400-5413.
8. Esteller M. (2007). Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 8: 286-298.
9. Feinberg AP, Ohlsson R, Henikoff S. (2006). The epigenetic progenitor origin of human cancer. Nat Rev Genet 7: 21-33.
10. Gius D, Cui H, Bradbury CM, Cook J, Smart DK, Zhao S et al. (2004). Distinct effects on gene expression of chemical and genetic manipulation of the cancer epigenome revealed by a multimodality approach. Cancer Cell 6: 361-371.
11. Gore SD, Baylin S, Sugar E, Carraway H, Miller CB, Carducci M et al. (2006). Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 66: 6361-6369.
12. Howard G, Eiges R, Gaudet F, Jaenisch R, Eden A. (2008). Activation and transposition of endogenous retroviral elements in hypomethylation induced tumors in mice. Oncogene 27: 404-408.
13. Issa JP, Kantarjian HM. (2009). Targeting DNA methylation. Clin Cancer Res 15: 3938-3946.
14. Jones BK, Levorse JM, Tilghman SM. (1998). Igf2 imprinting does not require its own DNA methylation or H19 RNA. Genes Dev 12: 2200-2207.
15. Jones PA, Baylin SB. (2007). The epigenomics of cancer. Cell 128: 683-692.
16. 0-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethyla-tion. Proc Natl Acad Sci USA 91: 11797-11801.
17. Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J et al. (2006). Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106: 1794-1803.
18. Lyko F, Brown R. (2005). DNA methyltransferase inhibitors and the establishment of epigenetic cancer therapies. J Natl Cancer Inst 97: 1498-1506. (Pubitemid 41631949)
19. Martianov I, Ramadass A, Serra Barros A, Chow N, Akoulitchev A. (2007). Repression of the human dihydrofolate reductase gene by a non-coding interfering transcript. Nature 445: 666-670.
20. Mazo A, Hodgson JW, Petruk S, Sedkov Y, Brock HW. (2007). Transcriptional interference: an unexpected layer of complexity in gene regulation. J Cell Sci 120: 2755-2761.
21. Mund C, Brueckner B, Lyko F. (2006). Reactivation of epigenetically silenced genes by DNA methyltransferase inhibitors: basic concepts and clinical applications. Epigenetics 1: 7-13.
22. 0-deoxycytidine in patients with myelodysplastic syndrome. Cancer Res 65: 7086-7090.
23. Nigumann P, Redik K, Matlik K, Speek M. (2002). Many human genes are transcribed from the antisense promoter of L1 retro-transposon. Genomics 79: 628-634.
24. Novakovic B, Wong NC, Sibson M, Ng HK, Morley R, Manuelpillai U et al. (2010). DNA methylation-mediated down-regulation of DNA methylatransferase-1 (DNMT1), is co-incident with, but not essential for, global hypomethylation in human placenta. J Biol Chem 285: 9583-9593.
25. 0-deoxycytidine (5-azadC) induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases (DNMTs) 1 and 3B. Mol Cell Biol 28: 752-771.
26. 0-deoxycytidine in human cancer cell lines. Blood 113: 659-667.
27. Rhee I, Bachman KE, Park BH, Jair KW, Yen RW, Schuebel KE et al. (2002). DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 416: 552-556.
28. Roman-Gomez J, Jimenez-Velasco A, Agirre X, Cervantes F, Sanchez J, Garate L et al. (2005). Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia. Oncogene 24: 7213-7223.
29. Santi DV, Norment A, Garrett CE. (1984). Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Proc Natl Acad Sci USA 81: 6993-6997.
30. Schuebel KE, Chen W, Cope L, Glockner SC, Suzuki H, Yi JM et al. (2007). Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet 3: 1709-1723.
31. Schulz WA, Steinhoff C, Florl AR. (2006). Methylation of endogenous human retroelements in health and disease. Curr Top Microbiol Immunol 310: 211-250.
32. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R et al. (2002). Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 20: 2429-2440. (Pubitemid 34525728)
33. Speek M. (2001). Antisense promoter of human L1 retrotransposon drives transcription of adjacent cellular genes. Mol Cell Biol 21: 1973-1985.
34. Stresemann C, Bokelmann I, Mahlknecht U, Lyko F. (2008). Azacytidine causes complex DNA methylation responses in myeloid leukemia. Mol Cancer Ther 7: 2998-3005.
35. Stresemann C, Brueckner B, Musch T, Stopper H, Lyko F. (2006). Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. Cancer Res 66: 2794-2800.
36. Vesely J, Cihak A, Sorm F. (1967). Biochemical mechanisms of drug resistance. IV. Development of resistance to 5-azacytidine and simultaneous depression of pyrimidine metabolism in leukemic mice. Int J Cancer 2: 639-646.
37. Walsh CP, Chaillet JR, Bestor TH. (1998). Transcription of IAP endogenous retroviruses is constrained by cytosine methylation. Nat Genet 20: 116-117.
38. Weisenberger DJ, Velicescu M, Cheng JC, Gonzales FA, Liang G, Jones PA. (2004). Role of the DNA methyltransferase variant DNMT3b3 in DNA methylation. Mol Cancer Res 2: 62-72.
39. 0-deoxycytidine therapy in patients with leukemia. Cancer Res 66: 5495-5503.
40. Yang AS, Estecio MR, Doshi K, Kondo Y, Tajara EH, Issa JP. (2004). A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic Acids Res 32: e38.